A Study to Evaluate the Safety and Efficacy of NEXAGON® (Lufepirsen Ophthalmic Gel) in Subjects With PCED

Clinical trial NCT05966493 · RECRUITING

Trial details

NCT number: NCT05966493
Sponsor: Glaukos Corporation
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Persistent Corneal Epithelial Defect

Start date: 2023-08-17
Primary completion: 2025-12-01
Enrollment: 84

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.